$396 Million is the total value of Affinity Asset Advisors, LLC's 73 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TRAVERE THERAPEUTICS INCnote 2.500% 9/1 | $7,056,000 | +17.7% | 7,000,000 | 0.0% | 1.78% | -16.9% | ||
| HSAQ | HEALTH SCIENCES ACQ CORP 2 | $2,967,000 | -3.0% | 300,000 | 0.0% | 0.75% | -31.6% | |
| MSAC | MEDICUS SCIENCES ACQUISITION | $2,925,000 | +1.0% | 300,000 | 0.0% | 0.74% | -28.7% | |
| GOSSAMER BIO INCnote 5.000% 6/0 | $2,087,000 | +30.0% | 2,000,000 | 0.0% | 0.53% | -8.3% | ||
| MREO | MEREO BIOPHARMA GROUP PLCads | $1,573,000 | -23.7% | 650,000 | 0.0% | 0.40% | -46.2% | |
| LSAQ | LIFESCI ACQUISITION II CORP | $1,470,000 | -2.0% | 150,000 | 0.0% | 0.37% | -30.9% | |
| SDGR | SCHRODINGER INC | $1,367,000 | -27.7% | 25,000 | 0.0% | 0.34% | -49.0% | |
| PCVX | VAXCYTE INC | $1,269,000 | +12.7% | 50,000 | 0.0% | 0.32% | -20.6% | |
| GLPG | GALAPAGOS NVspon adr | $1,052,000 | -24.2% | 20,000 | 0.0% | 0.27% | -46.5% | |
| IMTXW | IMMATICS N.V*w exp 07/01/2020 | $800,000 | +22.3% | 190,000 | 0.0% | 0.20% | -13.7% | |
| IMVT | IMMUNOVANT INCcall | $261,000 | -17.7% | 30,000 | 0.0% | 0.07% | -41.6% | |
| MSACW | MEDICUS SCIENCES ACQUISITION*w exp 02/12/2026 | $24,000 | -29.4% | 33,333 | 0.0% | 0.01% | -50.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MORPHIC HOLDING INC | 12 | Q3 2023 | 6.9% |
| KURA ONCOLOGY INC | 12 | Q3 2023 | 7.2% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 1.9% |
| IMMATICS N.V | 12 | Q3 2023 | 0.4% |
| CHINOOK THERAPEUTICS INC | 11 | Q2 2023 | 8.4% |
| ESTABLISHMENT LABS HLDGS INC | 11 | Q3 2023 | 8.3% |
| VINCERX PHARMA INC | 11 | Q2 2023 | 4.5% |
| ASCENDIS PHARMA A/S | 11 | Q3 2023 | 4.9% |
| CYTOKINETICS INC | 11 | Q3 2023 | 2.6% |
| INARI MED INC | 10 | Q1 2023 | 6.4% |
View Affinity Asset Advisors, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | July 03, 2023 | 7,477,000 | 9.2% |
View Affinity Asset Advisors, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-08-21 |
| 13F-HR | 2023-08-14 |
| SC 13G | 2023-07-03 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-13 |
View Affinity Asset Advisors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.